Low Dose Hydroxyurea is Effective in Reducing the Incidence of Painful Crisis and Frequency of Blood Transfusion in Sickle Cell Anemia Patients from Eastern India

REFERENCES

• Lanzkron S, Strouse JJ, Wilson R, . Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939–955.
   PubMed Web of Science ®Google Scholar
• Charache S, Dover GJ, Moore RD, . Hydroxyurea: effects on Hemoglobin F production in patients with sickle cell anemia. Blood. 1992; 79(10):2555–2565.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, . Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Kinney TR, Helms RW, O’Branski EE, . Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550–1554.
   Google Scholar
• Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009:62–69.
   Google Scholar
• Zimmerman SA, Schultz WH, Davis JS, . Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–2045.
   PubMed Web of Science ®Google Scholar
• Ferster A, Vermylen C, Cornu G, . Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):1960–1964.
   PubMed Web of Science ®Google Scholar
• Ferster A, Tariri P, Vermylen C, . Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–3632.
   PubMed Web of Science ®Google Scholar
• Maier-Redelsperger M, de Montalembert M, Flahault A, . Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood. 1998;91(12):4472–4479.
   PubMed Web of Science ®Google Scholar
• Ware RE. Summary of the evidence regarding efficacy of hydroxyurea treatment for sickle cell disease in children and adolescents. Proceedings of the Hydroxyurea Treatment for Sickle Cell Disease, An NIH Consensus Development Conference, held at the William H. Natcher Conference Center, National Institutes of Health, Bethesda, MD, USA on February 25-27 2008. 2008:29–32.
   Google Scholar
• Friedrisch JR, Prá D, Maluf SW, . DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res. 2008;649(1–2):213–220.
   PubMed Web of Science ®Google Scholar
• Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J. 2007;37(3):190–192.
   PubMed Web of Science ®Google Scholar
• Berthaut I, Guignedoux G, Kirsch-Noir F, . Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Hematologica. 2008;93(7):988–993.
   PubMed Web of Science ®Google Scholar
• Kar BC. Sickle cell disease in India. J Assoc Phys India. 1991;39(12):954–960
   PubMedGoogle Scholar
• Mashon RS, Dash PM, Khalko J, . Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis. Eur J Haematol. 2009;83(4):383–384.
   PubMed Web of Science ®Google Scholar
• Wu DY, Ugozzoli L, Pal BK, Wallace RB. Allele-specific enzymatic amplification of β-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA. 1989;86(8):2757–2760.
   PubMed Web of Science ®Google Scholar
• Old JM, Varawalla NY, Weatherall DJ. Rapid detection and prenatal diagnosis of β-thalassaemia: studies in Indian and Cypriot populations in the UK. Lancet. 1990;33(8719):834–837.
   Google Scholar
• Charache S, Terrin ML, Moore RD, . Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials. 1995;16(6):432–446.
   PubMedGoogle Scholar
• Mukherjee MB, Surve RR, Gangakhedkar RR, Ghosh K, Colah RB, Mohanty D. β-Globin gene cluster haplotypes linked to the βS gene in western India. Hemoglobin. 2004;28(2):157–161.
   PubMed Web of Science ®Google Scholar
• Braga LB, Ferreira AC, Guimarães M, . Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study. Hemoglobin. 2005;29(3):171–180.
   Web of Science ®Google Scholar
• Italia K, Jain D, Gattani S, . Hydroxyurea in sickle cell disease—a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25–31.
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Rodgers GP, Serjeant GR, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318(2):96–99.
   Google Scholar
• Ware RE, Eggleston B, Redding-Lallinger R, . Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10–14.
   PubMed Web of Science ®Google Scholar
• Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. Hydroxyurea therapy requires Hb F induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599–1603.
   PubMed Web of Science ®Google Scholar
• Platt OS. Hydroxyurea for the treatment of sickle cell anaemia. N Eng J Med. 2008;358(13):1362–1369.
   PubMed Web of Science ®Google Scholar
• Orringer EP, Blythe DS, Johnson AE, Phillips G Jr, Dover GJ, Parker JC. Effects of hydroxyurea on Hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anaemia. Blood. 1991;78(1):212–216.
   Google Scholar
• Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000;109(2):322–327.
   PubMed Web of Science ®Google Scholar
• Wiles N, Howard J. Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. Ther Clin Risk Manag. 2009;5:745–755.
   PubMedGoogle Scholar
• Lima CS, Arruda VR, Costa FF, Saad ST. Minimal doses of hydroxyurea for sickle cell disease. Braz J Med Biol Res. 1997; 30(8):933–940.
   Google Scholar
• Al-Nood HA, Al-Khawlani MM, Al-Akwa A. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin. 2011;35(1):13–21.
   PubMed Web of Science ®Google Scholar